N-terminal and C-terminal heparin-binding domain polypeptides derived from fibronectin reduce adhesion and invasion of liver cancer cells by Tang, Nan-Hong et al.
RESEARCH ARTICLE Open Access
N-terminal and C-terminal heparin-binding
domain polypeptides derived from fibronectin
reduce adhesion and invasion of liver cancer cells
Nan-Hong Tang
1, Yan-Lin Chen
1, Xiao-Qian Wang
1, Xiu-Jin Li
1, Yong Wu
2, Qi-Lian Zou
3, Yuan-Zhong Chen
2*
Abstract
Background: Fibronectin (FN) is known to be a large multifunction glycoprotein with binding sites for many
substances, including N-terminal and C-terminal heparin-binding domains. We investigated the effects of highly
purified rhFNHN29 and rhFNHC36 polypeptides originally cloned from the two heparin-binding domains on the
adhesion and invasion of highly metastatic human hepatocellular carcinoma cells (MHCC97H) and analyzed the
underlying mechanism involved.
Methods: The MHCC97H cells that adhered to FN in the presence of various concentrations of rhFNHN29 and
rhFNHC36 polypeptides were stained with crystal violet and measured, and the effects of rhFNHN29 and rhFNHC36
on the invasion of the MHCC97H cells were then detected using the Matrigel invasion assay as well as a lung-
metastasis mouse model. The expression level of integrins and focal adhesion kinase (FAK) phosphotyrosyl protein
was examined by Western blot, and the activity of matrix metalloproteinases (MMPs) and activator protein 1 (AP-1)
was analyzed by gelatin zymography and the electrophoretic mobility band-shift assay (EMSA), respectively.
Results: Both of the polypeptides rhFNHN29 and rhFNHC36 inhibited adhesion and invasion of MHCC97H cells;
however, rhFNHC36 exhibited inhibition at a lower dose than rhFNHN29. These inhibitory effects were mediated by
integrin avb3 and reversed by a protein tyrosine phosphatase inhibitor. Polypeptides rhFNHN29 and rhFNHC36
abrogated the tyrosine phosphorylation of focal adhesion kinase (p-FAK) and activation of activator protein 1
(AP-1), resulting in the decrease of integrin av, b3 and b1 expression as well as the reduction of MMP-9 activity.
Conclusions: Polypeptides rhFNHN29 and rhFNHC36 could potentially be applicable to human liver cancer as anti-
adhesive and anti-invasive agents.
Background
Invasion and metastasis are important biological charac-
teristics of malignant tumors. Metastatic formation
requires specific cell-to-cell and cell-to-extracellular
matrix (ECM) interactions mediated by integrins [1],
cadherins [2], selectins [3], etc. In particular, integrin-
mediated adhesion of tumor cells to ECM proteins and
cell surface components is considered a crucial event in
metastasis. Accordingly, the prevention of tumor cell
adhesion to ECM proteins has been an area of interest
as a potential target for therapeutic intervention [4-6].
Fibronectin (FN) is a type of adhesive-attraction glyco-
protein. Previous studies have shown that the anchoring
of FN to ECM in vitro plays an important role in cancer
cell metastasis [7]. Moreover, the study of FN expression
on cancer cells has determined that decreased FN
expression is closely associated with cancer growth and
metastasis [8-10], which illustrates that an increase of
FN expression in cancer cells may conversely facilitate
the reduction of cancer cell metastasis, implying that FN
may have the potential for a significant clinical applica-
tion. Interestingly, our in vitro intervention experiments
showed that free FN could inhibit the adhesion and
metastasis of hepatocellular carcinoma cells. It is possi-
ble that the exposed cell binding site may not be the
same in FN between free-status and anchoring-status.
Therefore, the free FN has potential value for a
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any medium, provided the original work is properly cited.therapeutic application. However, obstacles exist for the
clinical application of FN, including deficiency of blood
plasma, danger of blood-infection disease, and difficulty
in engineering the synthesis of the whole-molecule FN
with a molecular weight as large as 420 kDa. Fortu-
nately, FN contains several active sites that serve as scaf-
foldings for cell anchorage [11], known as the heparin-
binding domains, collagen-binding domain, fibrin-bind-
ing domain and cell-binding domain, respectively. These
domains are involved in a diverse array of cell functions
including adhesion, migration, differentiation, apoptosis,
morphous change, haemostasis and reparation of
damage, etc. Therefore, the replacement of FN with a
polypeptide derived from a FN functional domain is
considered to be a more feasible method for cancer
treatment. Several reports have highlighted this type of
application; for example, it has been found that argi-
nine-glycine-aspartic acid (RGD) integrin-binding motif
from FN containing the adhesion recognition signal
Arg-Gly-Asp partially inhibit intrahepatic metastasis of
murine hepatocellular carcinoma (HCC) [12]. The CH50
polypeptide that contains Cell I and Hep II dual domain
fragment of FN has been shown to play a role involving
inhibition of tumor growth, invasion and angiogenesis
[13]. The FNIII14 peptide also effectively inhibited the
adhesion and metastasis of lymphoma cells [14].
Heparin-binding domains are important molecular
structures of FN: one (237 mer) at the N-terminal con-
tains five I-type homologous structures [15], and
another (272 mer) at the C-terminal contains three type
III homologous structures [16]. In previous studies we
obtained purified recombinant N-terminal and C-term-
inal heparin-binding domain polypeptides of FN
(rhFNHN29 and rhFNHC36) using genetic engineering,
further testing their characteristics with heparin-binding
activity measurements [17]. However, the function of
these fragments concerning cancer therapy was still
unknown. In this study we investigated the effects of
rhFNHN29 and rhFNHC36 on the adhesion and inva-
sion of highly metastatic human HCC cells (MHCC97H)
and analyzed the underlying mechanism.
Methods
Reagents, Cell Culture, and Animal Model
T h er e a g e n t sf o rt h ep r o d u c t i o no fr h F N H N 2 9a n d
rhFNHC36 were purchased: restriction enzyme XhoI,
EcoRI, BamHI, HindIII, Bgl II and T4 ligase from Pro-
mega Co.; vector pPIC9K, pGEM-T, pAo815SM and
GS115 yeast cells from Invitrogen Co.; purification col-
u m nS - 1 0 0 ,S Pa n dH i T r a pH e p a r i nH Pc o l u m nf r o m
GE Co. BSA, type I collagen, type IV collagen and FN
were purchased from Sigma Co.; and anti-FN pAb, anti-
integrin av( P 2 W 7 ) ,b3( B V 4 ) ,b1 (8A2) mAb and anti-
p-FAK mAb were purchased from Santa Cruz
Biotechnology, Inc. Liver carcinoma cell lines
(MHCC97H and MHCC97L) were purchased from
Liver Cancer Institute of Fudan University (Shanghai,
China) and maintained in DMEM medium supplemen-
ted with 10% fetal bovine serum (GIBCO) in a 5.0%
CO2 incubator at 37°C [18]. Huh-7, HepG2, BEL7404
and SMMC7721 cells were maintained in our labora-
tory. Male BALB/c nude mice at the age of 5 to 6 weeks
were purchased from the Chinese Academy of Sciences
(Shanghai) and were given humane care according to
the criteria outlined in the “Guide for the Care and Use
of Laboratory Animals” prepared by the National Acad-
emy of Sciences and published by the National Institutes
of Health (NIH publication 86-23 revised 1985). The
experimental protocol was approved by the Medical
Experimental Animal Care Committee of Fujian Medical
University.
Production of rhFNHN29 and rhFNHC36
According to the structural features of yeast expression
v e c t o rp G E M - T ,P C Rp r i m e r st oc l o n et h er h F N H N 2 9
and rhFNHC36 genes were designed and the sequences
of these primers are as follows:
5′-ATGCTC
↓TCGAGAAAAGAGAGGCTGAAGC-
TAGTCAAAGCAAGCCCGGTTGTTA-3′(rhFNHN29-F),
5′-ACGTAG
↓AATTCTCCGCTCGATGTGGTCTGCA-3′
(rhFNHN29-R), 5′-CGG
↓GATCCGCTATTCCTGCAC-
CAACTGAC-3′(rhFNHC36-F) and 5′-CCCA
↓AGCTTC
TCGTCTGTCTTTTTCCTTCC-3′(rhFNHC36-R), which
contain XhoI/EcoRIa n dBamHI/HindIII sites (underlined),
respectively.
The rhFNHN29 gene was then cloned into the inte-
grated yeast expression vector pPIC9K through the tran-
sition of the pGEM-T and pAo815SM vector. The
recombinant plasmid of pPIC9K-FNHN29 was con-
firmed by restriction analysis and sequenced upon trans-
fection of competent DH5a E.coli cells and selection of
resistant clones. The pPIC9K-FNHN29 plasmid was
extracted, digested by BglII enzyme, and transferred into
the GS115 yeast cells. The resistant clone with high
expression was cultured for amplification. The fermenta-
tion liquid was precipitated using 80% ammonium sul-
fate, and then the dissolved sediments were purified
using an S-100 column and an SP column. The UV280
waveform of the purified liquid was monitored by
HPLC. The collected peak waveform sample was
detected by SDS-PAGE electrophoresis and western blot
analysis for FN antigenicity. The yeast fermentation
supernatant of rhFNHN29 was diluted by 5 mM PBS
with an adjusted 7.0 pH value and conductivity less than
4.0 and then eluted on a HiTrap Heparin HP column.
HPLC was used to monitor the UV280 waveform of the
purified liquid. The collected peak waveform sample
was measured by mass spectrometry to determine the
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procedure for the recombinant yeast expression vector
of rhFNHC36 was identical to the procedure above.
Semiquantitative RT-PCR Analysis
RNA was isolated from the cell lines with Trizol (Invitro-
gen, USA) and was then reverse-transcribed. Fragments of
integrin a4( 2 9 6b p ) ,a5( 3 6 2b p ) ,av (236 bp), b1( 4 0 7
bp) and b3( 3 2 7b p ) ,a n dM M P - 1( 4 2 8b p ) ,M M P - 2( 3 9 0
bp), MMP-9 (215 bp) and b-actin (500 bp) cDNA were
amplified by PCR. The primer sequences were as follows:
integrin a4, sense 5′-CAACACGCTGTTCGGCTAC-3′
and antisense (AS) 5′-TATGCCCACAAGTCACGATG-3′;
integrin a5, sense 5′-CCGAATTCTGGAGTATGCAC-3′
and AS 5′-TGGTGACATAGCCGTAAGTG-3′;i n t e g r i n
av, sense 5′-GGAGCAATTCGACGAGCACT-3′ and AS
5′-GCAGGCGTGAACTGGTTAAG-3′; integrin b1, sense
5′-TGAAGGGCGTGTTGGTAGAC-3′ and AS 5′-GCCC
TTGAAACTTCGGATCT-3′; integrin b3, sense 5′-CAC-
CAGTAACCTGCGGATTG-3′ and AS 5′-GTCTTGG
CATCAGTGGTAAAC-3′; MMP-1, sense 5′-CTGAAGGT
GATGAAGCAGCC-3′ and AS 5′-AGTCCAAGA-
GAATGGCCGAG-3′;M M P - 2 ,s e n s e5 ′-GCGACAA-
GAAGTATGGCTTC-3′ and AS 5′-TGCCAAGGTCA
ATGTCAGGA-3′; MMP-9, sense 5′-AGTTCCCGGAGT-
GAGTTGAA-3′ and AS 5′-CTCCACTCCTCCCTT
TCCTC-3′; b-actin sense, 5′-ATGTCACGCAC-
GATTTCCCGC-3′ and AS 5′-GGCATGGGTCAGAAG-
GATTCC-3′.
Cell Adhesion Assay
Part 1: The MHCC97H cell suspensions (2×10
5/100 μl)
with or without Mn
2+ (0.1 mM) were added to 96-well
plates coated with either BSA, type I collagen, type IV
collagen, or FN at 20 μg/ml. After the above incubation
at 37°C for 1 h, cells were fixed with formalin, and sepa-
rated cells were washed off with PBS [19]. Cells that
adhered to the substrate were stained with crystal violet.
Dye bound to adhered cells was solubilized with 0.1%
SDS, and absorbance at 590 nm was measured. The
data represent the mean value of three determinations.
Part 2: The MHCC97H cell suspensions (2 × 10
5/100
μl) containing Mn
2+ (0.1 mM) were pretreated with
function-blocking mAb to av( P 2 W 7 ) ,b3( B V 4 )o rb1
(8A2) and control IgG at different concentrations (6, 12,
25 and 50 μg/ml), respectively, and were then seeded in
96-well plates coated with FN (20 μg/ml). The following
procedures were identical to Part 1 above. Part 3: The
MHCC97H cell suspensions (2 × 10
5/100 μl) containing
Mn
2+ (0.1 mM) were pretreated with or without 25 μg/
ml mAb to av( P 2 W 7 ) ,b3( B V 4 )o rb1 (8A2) and con-
trol IgG, respectively, and were then seeded in 96-well
plates coated with FN (20 μg/ml) or poly-L-Lys (20 μg/
ml) in the presence or absence of FN, rhFNHN29 and
rhFNHC36 at three different concentrations (50, 100
and 200 μg/ml). The procedure that follows is identical
to Part1 above.
Matrigel Invasion Assay
Transwell culture inserts with an 8-mm pore-size PET
membrane precoated with 20 μgM a t r i g e l( B D ,U S A )
were transferred to a new 24-well plate. The bottom
chambers were coated with 10 μlF N( 0 . 5m g / m l )a n d
air-dried. The MHCC97H cell suspension (5 × 10
4/100
μl) containing Mn
2+ (0.1 mM) was then treated with or
without FN, rhFNHN29 and rhFNHC36 (50, 100 and
200 μg/ml) at 37°C for 1 h, and control IgG, or anti-av
(P2W7), -b3( B V 4 )o r- b1( 8 A 2 )( 2 5μg/ml) was then
added to the top chambers, respectively. After 48 h
incubation, the inserts were dipped into a fixing solution
(containing 95% ethanol and 5% acetic acid) for 30 min,
and the non-invading cells were removed from the
upper surface of the membrane by scrubbing with a cot-
ton swab. The cells on the lower surface of the mem-
brane were stained with H&E. Cells from five different
fields were counted under an inverted microscope at
100-fold magnification and the mean was calculated.
Experiments of Lung Metastasis
1×1 0
7 cells in a 0.2 ml volume of normal saline (NS)
were inoculated subcutaneously into the right flank of
nude mice. Seven days later, a tumor (approximately 5
mm in diameter) appeared at the cell inoculation site in
each nude mouse model. 32 of the tumor-bearing nude
mice were divided randomly into 4 groups (n = 8 per
group), and then injected with NS (100 μle a c ht i m e ) ,
FN, rhFNHN29 and rhFNHC36 (200 μg in 100 μlN S
each time), respectively, at the tumor cell inoculation
site for 7 consecutive days. At the end of 6 wk, all of
the mice were sacrificed, and the lungs were excised,
fixed in formalin, imbedded in paraffin, and cut into 4-
μm consecutive sections and stained with H&E. Each
metastatic focus in the lung was identified as it appeared
at the same site on consecutive sections. Finally, all
determined foci were counted to evaluate metastasis his-
tologically [20,21]. Three pathologists performed the
counting independently and in a blinded manner.
MMP Activity
The MHCC97H cell (1.2 × 10
6)s u s p e n s i o n sw e r e
seeded into 6-well plates in DMEM supplemented with
10% FBS and Mn
2+ in the absence or presence of differ-
ing concentrations of rhFNHN29 and rhFNHC36. After
24 h, cells were incubated in serum-free DMEM for
24 h. The supernatants were collected after centrifuga-
tion and the cells were trypsinized and counted. An
assay to measure MMP activity was performed using
Gelatin Zymography according to Iwai’s report [22].
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non-denaturing conditions into a zymogram gel supple-
mented with 0.1% gelatin to detect the presence of
MMP-2 and -9. Electrophoresis was performed at a con-
stant voltage of 120 V for 90 min. Gels were washed in
a re-naturing buffer and incubated in an incubation buf-
fer at 37°C for 24 h, stained with Coomassie brilliant
blue R-250 (Sigma), and then de-stained with gel-clear
de-stain solution. Areas of gelatinolytic degradation
appeared as transparent bands on the blue background.
The enzymolysis strip volume [area × (gray stripe-gray
background)] is expressed as the mean ± SD of the tri-
plicate experiment for each group.
Western Blot Analysis of Integrin Protein
T h eM H C C 9 7 Hc e l l sw e r ec u l t u r e da sp e rt h ep r o c e s s
described in “MMP activity”.5 0μg samples of cell extract
were run on 10% SDS-PAGE gels and electro-blotted to
NC membranes, which were then visualized by anti-integ-
rin av, b3a n db1 mAb, followed by HRP-labeled anti-
mouse IgG and detected by enhanced chemiluminescence
(ECL). The relative amount of each protein band was
quantified as a ratio to the b-actin band indicated under-
neath each gel using the densitometric scanning software
Quantity One (BIO-RAD). The data are expressed as the
mean ± SD of the three independent experiments.
Protein Tyrosine Phosphorylation
MHCC97H cells were incubated in serum-free DMEM
f o r1 0h ,t h e ni nD M E Mw i t ho rw i t h o u tp h e n y l a r s i n e
oxide (PAO, 20 μM) for 5 min, and further in DMEM
with Mn
2+ (0.1 mM) in the presence or absence of FN,
rhFNHN29 and rhFNHC36 (200 μg/ml) at 37°C for 20
min. Cell nuclear proteins were extracted and the phos-
photyrosyl proteins (p125
FAK) electroblotted to PVDF
membrane were visualized by anti-p-FAK (Tyr 397)
after SDS-PAGE, followed by HRP-labeled antirabbit
IgG and were detected by ECL.
Electrophoretic Mobility Band-Shift Assay (EMSA)
T h eM H C C 9 7 Hc e l l sw e r ec u l t u r e da sp e rt h ep r o c e s s
described in “Protein tyrosine phosphorylation”. According
to EMSA Kit (Viagene, USA) manufacturer instructions, 7
μg of nuclear proteins were extracted and incubated with
the biotin-labeled activator protein 1 (AP-1) double-
stranded oligonucleotides probe (5′-CGCTTGATGACT-
CAGCCGGAA-3′/3′-GCGAACTACTGAGTCGGCCTT-
5′) in a binding buffer for 20 min at room temperature, and
the activated AP-1 was then electroblotted to a nylon mem-
brane and visualized after 6.5% PAGE.
Statistical Analysis
Results are shown as the mean ± SD. One-way ANOVA
(analysis of variance) followed by Fisher’sL e a s t
Significant Difference post hoc test or Tamhane’sT 2
test (if equal variance is not assumed) was used for
comparison of data from different groups. Differences
with P < 0.05 were considered statistically significant.
For the counting of the lung metastatic foci, the Intra-
class Correlation Coefficient (ICC) value was used to
evaluate the inter-observer variability (reproducibility)
by the reliability analysis of SPSS (Statistical Product
and Service Solutions).
Results
Purification and Heparin Affinity of rhFNHN29 and
rhFNHC36 Polypeptides
The N-terminal heparin-binding domain polypeptide of
FN consists of five I homologous structures (Figure 1A),
containing 237 amino acids (Ser46-Gly282). The length
of the DNA sequence encoding this polypeptide is 711
bp (403 bp-1113 bp). In this study, the PCR amplified
fragment was 741 bp, and the double-digested fragment
was 729 bp. The C-terminal heparin-binding domain
polypeptide of FN consists of three III homologous
structures (III-12, III-13 and III-14) (Figure 1A), con-
taining 272 amino acids (Tyr1720-Tyr1991). The length
of the DNA sequence encoding this polypeptide is 816
bp (5428 bp-6244 bp). In this study, the PCR amplified
fragment was 835 bp, and the double-digested fragment
was 828 bp. We named the two polypeptides
rhFNHN29 and rhFNHC36, respectively.
Upon obtaining yeast expression vectors pPIC9K-
FNHN29 and pPIC9K-FNHC36, we successfully estab-
lished yeast strains GS115-FNHN29 and KM71-
FNHC36 that exhibited high expression. The purity of
rhFNHN29 and rhFNHC36 polypeptides, which were
purified from fermentation supernatant through centri-
fugalization, ultrafiltration, ion exchange chromatogra-
phy, and sieve chromatography (Figure 1B), was over
95%. Western blot confirmed the detection of
rhFNHN29 and rhFNHC36 with FN polyclonal antibody
(Figure 1C). Heparin affinity chromatography indicated
that rhFNHN29 and rhFNHC36 display the activity of
binding heparin (Figure 2A). Mass spectrometry analysis
provided evidence that the molecular weights were 27.9
kDa and 31.0 kDa, respectively (Figure 2B).
Expression Pattern of Integrins and MMPs in Human Liver
Cancer Cell Lines
Some previous studies have demonstrated that different
expression levels of integrins and matrix metalloprotei-
nases (MMPs) exhibit different abilities in adhesion and
invasion of tumor cells that in turn influence the inter-
action between the cells and extracellular matrix [23,24].
However, little is known regarding integrin and MMP
expression patterns in liver cancer. We are the first to
investigate the potential impact of rhFNHN29 and
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cells by comparing the mRNA expression level of integ-
r i n sa n dM M P si nM H C C 9 7 Hc e l l s( h i g h l yi n v a s i v e )
with the expression level found in other human liver
cancer cell lines using RT-PCR. The results showed no
mRNA expression of integrin a4, low expression levels
of integrin a5 mRNA and high levels of integrin av,
integrin b1, integrin b3, MMP1, MMP2 and MMP9
mRNA expression in the MHCC97H cell line (Figure 3).
Overall, the MHCC97H cell line appears to be a suitable
cell model in order to evaluate the therapeutic potential
for rhFNHN29 and rhFNHC36 on invasion and metas-
tasis of liver cancer cells.
RhFNHN29 and RhFNHC36 Inhibit MHCC7H Cell Adhesion
and Migration Induced by Integrin avb3
Based on the results above, we further assessed the anti-
adhesive effects of rhFNHN29 and rhFNHC36 on
MHCC97H cells. As shown in Figure 4A, MHCC97H
cells adhered well to the FN substrate, but adherence
was dependent on Mn
2+ and was affected slightly by
BSA and types I and IV collagen substrates. On the
other hand, as shown in Figure 4B, we carried out an
adhesion inhibition experiment using anti-av( P 2 W 7 )
and anti-b3 (BV4) mAb at different concentrations (6,
12, 25 and 50 μg/ml) to verify the type of integrin that
mediates adhesion of liver cancer cells to FN. The
r e s u l t ss h o w e dt h a ta n t i - av( P 2 W 7 )a n da n t i - b3( B V 4 )
mAb obviously inhibit MHCC97H cell adhesion to FN
at 25 μg/ml, while the differences of the effects of anti-
b1 (8A2) on inhibition was not obvious at other con-
centrations. Thus, we chose 25 μg/ml as the antibody
concentration for follow-up experiments. As shown in
Figure 4C, MHCC97H cell adhesion to the FN substrate
was blocked by anti-av (P2W7) and anti-b3 (BV4) mAb,
but not by anti-b1 (8A2) mAb. RhFNHC36 inhibited
MHCC97H cell adhesion to the FN substrate in a dose-
dependent manner. RhFNHN29 and FN also inhibited
adhesion of MHCC97H cells to the FN substrate
but required high concentrations. RhFNHN29 and
rhFNHC36 did not affect nonspecific adhesion of
MHCC97H cells to poly-L-Lys substrate.
When we performed the cell invasion assay using
Transwell chambers, as shown in Figure 4D, the
Figure 1 Expression of purified rhFNHN29 and rhFNHC36 polypeptides.( A ) ,S c h e m a t i cs t r u c t u r eo fF N .F Ni sm a d eu po fas e r i e so f
repeating homology units of three different types (FNI, FNII and FNIII). Yellow rectangles represent FNI modules, blue rhombus represent FNII
modules and red ovals represent specific FNIII modules. RhFNHN29 containing N-terminal heparin-binding domain (HBD) is comprised of the FNI
1-5 modules, and rhFNHC36 containing C-terminal HBD is comprised of the FNIII12-14 modules. (B), Purified rhFNHN29 and rhFNHC36
polypeptides were subjected to SDS-PAGE and visualized by Coomassie Blue staining. (C), The purified rhFNHN29 and rhFNHC36 polypeptides
were analysed by Western blot. Immunoreactive fragments of 27.9 kDa and 31.0 kDa indicated their antigenicity.
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Page 5 of 13Figure 2 Heparin affinity analysis of rhFNHN29 and rhFNHC36 polypeptides. (A), The chromatography showed the peak fractions (Arrow)
of eluted rhFNHN29 and rhFNHC36 polypeptides on a column (1 ml) of HiTrap Heparin HP at a flow rate of 1.5 ml/min. (B), LC/MS analysis
indicated the elution position of molecular weight for purified rhFNHN29 (27.897 kDa) and rhFNHC36 polypeptides (31.051 kDa).
Figure 3 Standard RT-PCR analysis of different integrins or MMP expression in human liver cancer cell lines. Total RNA was isolated
from human liver cancer cell lines and subsequently reverse-transcribed and analysed by PCR amplification for expression of integrin a4, a5, av,
b1 and b3( A), MMP1, MMP2 and MMP9 (B) and, as internal control, b-actin (lower panel). Cell lines are as follows: SMMC7721, BEL7404, HepG2,
Huh-7, MHCC97L and MHCC97H.
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Page 6 of 13Figure 4 RhFNHN29 and rhFNHC36 inhibit MHCC97H cell adhesion to FN substrate and migration toward FN. (A), MHCC97H cell
suspension (2 × 10
5/100 μl) with or without Mn
2+ (0.1 mM) was added to a 96-well plate coated with either BSA, type I collagen (20 μg/ml),
type IV collagen (20 μg/ml) or FN (20 μg/ml). (B), Effects of different antibody concentrations (6, 12, 25 and 50 μg/ml) on MHCC97H cell
adhesion to FN. (C), MHCC97H cell suspension (2 × 10
5/100 μl) containing Mn
2+ (0.1 mM) was pretreated with or without 25 μg/ml control IgG
and function-blocking mAb to av (P2W7), b3 (BV4) or b1 (8A2), respectively, and then seeded to a 96-well plate coated with FN (20 μg/ml) or
poly-L-Lys (20 μg/ml) in the presence or absence of FN, rhFNHN29 and rhFNHC36 (50, 100 and 200 μg/ml), respectively. The data represent the
mean ± SD of three determinations. (D), A cell invasion assay was carried out in blind-well chambers. MHCC97H cell suspension (5 × 10
4/100 μl)
containing Mn
2+ (0.1 mM) treated with or without FN, rhFNHN29 and rhFNHC36 (50, 100 and 200 μg/ml), and control IgG, or anti-av (P2W7), -b3
(BV4) or -b1 (8A2) (25 μg/ml) were incubated at 37°C for 1 h and then added to the top chambers, respectively. After incubation for 48 h, the
number of cells migrating across the Matrigel-coated filter into the bottom chamber was counted. The data represent the mean ± SD of three
determinations. (E), Compared with the morphous of MHCC97H cells under normal conditions (×200 magnification), representative pictures for
migrated MHCC97H cells on the bottom chamber (×100 magnification) in the presence of FN, rhFNHN29 and rhFNHC36 (200 μg/ml) showed a
fibroblastic appearance.
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ter into the bottom chamber in response to FN, which
was prevented by anti-av( P 2 W 7 )a n da n t i - b3( B V 4 )
mAb; migration was not prevented by anti-b1( 8 A 2 )
mAb, indicating that ligation of avb3 induced the inva-
sion of MHCC97H cells. RhFNHC36 inhibited the FN-
induced, integrin avb3-mediated invasion of MHCC97H
cells at a lower dose. RhFNHN29 and FN also affected
the invasion of MHCC97H cells to the FN substrate but
required higher concentrations.
RhFNHN29 and RhFNHC36 Decrease Experimental
Metastasis of MHCC97H Cells
MHCC97H cells exhibit lung metastasis from primary
lesions in nude mice [18]. We further investigated the
effect of rhFNHN29 and rhFNHC36 on the lung metas-
tasis of MHCC97H cells. Six weeks after MHCC97H
cells were inoculated subcutaneously into nude mice,
metastasis in the lungs was carefully observed on serial
microscopic sections of whole specimens in all mice. As
s h o w ni nF i g u r e5 ,F N ,r h F N H N 2 9a n dr h F N H C 3 6
intervention groups resulted in a mean number of
tumor colonies of 7.1 ± 1.1, 7.3 ± 1.3, and 5.9 ± 1.2,
respectively. In contrast, the mean number of lung
tumor colonies in the NS group was 8.9 ± 1.6. The lung
metastasis of MHCC97H cells was inhibited significantly
in nude mice by rhFNHN29 and rhFNHC36 (P < 0.05),
and the inhibition of rhFNHC36 was more effective
than that of rhFNHN29 (P < 0.05). Our data suggested
t h a tr h F N H N 2 9a n dr h F N H C 3 6m i g h tp l a yar o l ei n
reducing migration and invasion of MHCC97H cells.
RhFNHN29 and RhFNHC36 Reduce Integrin Expression
and MMP Activity
To verify whether the changes in integrin and MMP
expression contributed to the reduction of adhesion and
invasion of MHCC97H cells by intervention of rhFNHN29
and rhFNHC36, we evaluated the expression of related
Figure 5 Effect of rhFNHN29 and rhFNHC36 on metastatic tumor colonies. Representative pictures of metastasis in lungs of the nude mice
6 wk after MHCC97H cell inoculation and being subjected to intervention by NS, FN, rhFNHN29 and rhFNHC36 (HE staining × 100 ®lung
metastasis). The group data represent the mean ± SD (n = 8). * denotes a statistically significant difference compared to the control (P < 0.05)
and # denotes a statistically significant difference with rhFNHN29 (P < 0.05) by One-Way ANOVA.
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MHCC97H cells. As shown in Figure 6A, rhFNHN29 and
rhFNHC36 affected the expression of integrin av, b3 and
b1 in a dose-dependent manner. Furthermore, integrin av
and b3 expression were almost lost as the cells were trea-
ted with rhFNHC36 at a high concentration (200 μg/ml).
This indicated that the effectiveness of rhFNHC36 was
stronger than that of rhFNHN29. In addition, the impact
of rhFNHN29 and rhFNHC36 on activity of proMMP-2
was not significant, but the impact of rhFNHC36 on activ-
ity of actMMP-9 and proMMP-9 was significant with con-
centration-dependence (Figure 6B). Taken together, these
results account for the decrease of adhesion and invasion
of MHCC97H cells.
Inhibition of Adhesion and Migration by RhFNHN29 and
RhFNHC36 Correlates with Tyrosine Phosphorylation of
FAK and Activation of AP-1
Protein tyrosine phosphorylation of FAK is considered
to play a crucial role in integrin-mediated signaling
events. To further elucidate the molecular mechanism
and investigate the extended integrin specificity of
rhFNHN29 and rhFNHC36, we examined the effect of
phenylarsine oxide (PAO), a protein tyrosine phospha-
tase inhibitor [25], on the anti-adhesive activity of
rhFNHN29 and rhFNHC36. As shown in Figure 7A, the
inhibitory effect of rhFNHN29 and rhFNHC36 on
MHCC97H cell adhesion to the FN substrate was
reversed by the addition of PAO, although PAO itself
had no effect on MHCC97H cell adhesion. Next, we
observed tyrosine phosphorylation of FAK (p125
FAK)
and activation of AP-1 involved in adhesion and migra-
tion signaling. When MHCC97H cells were stimulated
in the presence of Mn
2+, rhFNHN29 and rhFNHC36,
p125
FAK and activated AP-1 remained only at basal
levels. The decreased p125
FAK and AP-1 were restored
by the addition of PAO (Figure 7B).
Discussion
As the recurrence and metastasis of HCC remains a for-
midable problem in clinical practice, many efforts have
been made to develop a more efficient treatment to
Figure 6 Reduction of integrin expression and MMP activity by rhFNHN29 and rhFNHC36. (A-1), Representative immunoblots for integrin
av, b3 and b1 proteins. (A-2), The group data represents the mean ± SD (n = 3). The densitometry data were normalized to b-actin. * denotes a
statistically significant difference compared to the control (P < 0.05) and # denotes a statistically significant difference compared to rhFNHN29 at
the same concentration (P < 0.05) by One-Way ANOVA. (B-1), Analysis of MMP activity. Supernatants from MHCC97H cells cultured with Mn
2+ in
the absence or presence of different concentrations of rhFNHN29 and rhFNHC36 were performed by Gelatin Zymography. (B-2), The group data
of enzymolysis strip volume represent mean ± SD (n = 3). * denotes a statistically significant difference compared to the control (P < 0.05) and #
denotes a statistically significant difference compared to rhFNHN29 at the same concentration (P < 0.05) by One-Way ANOVA.
Tang et al. BMC Cancer 2010, 10:552
http://www.biomedcentral.com/1471-2407/10/552
Page 9 of 13inhibit or prevent tumor metastasis. As the expression
level of integrins on HCC cells and in the extracellular
matrix is related closely to a cell’s ability to migrate
[26,27], attempts to realize “anti-adhesion therapy” have
been undertaken using synthetic integrin-binding pep-
tides derived from cell adhesive sites of ECM protein. A
number of previous studies have proposed that syn-
thetic peptides which contain the RGD cell adhesion
motif common in several ECM proteins, including FN,
have the potential to prevent tumor metastasis [28].
However, the application of these short peptides is lim-
ited due to high dosage requirement and short half-life.
To overcome these difficulties, various chemical modifi-
cations of the integrin-binding peptides have been per-
formed in order to enhance integrin binding affinity
[29,30]. A synthetic peptide derived from the 14th type
I I Im o d u l ew e a k e n st h ei n t e g r i na5b1-mediated adhe-
sion of various cell types to the FN substrate in a rever-
sible manner [14]. Wang [31] designed a derivative of
synthesized peptides containing anti-adhesion peptide b
(DLYYLMDLSYSMK), in accordance with the conserved
sequence of the integrin a and b unit. Liu [13] demon-
strated that treatment with the gene delivery technique
resulting in in vivo expression of a recombinant CBD-
HepII bifunctional-domain polypeptide of FN, desig-
nated as CH50, inhibited tumor metastasis to the liver.
However, the impact of this gene therapy on liver cells
themselves has not been investigated.
The present study demonstrated that the polypeptides
derived from FN, rhFNHN29 and rhFNHC36, have the
a b i l i t yt or e d u c eb y~ 3 0 %t h en u m b e ro fl u n gm e t a s -
tases of MHCC97H cells in the nude mice metastasis
model. This efficacy might be explained as less degrada-
tion with longer fragment and less of an effect on the
model organism with non-chemical modification and
non-gene expression in cells. The mechanisms underly-
ing the inhibition may be very complex, yet they were
identified in this study as follows.
First of all, rhFNHN29 and rhFNHC36 could interfere
with the function of integrin ava n db3. As to the
avb3-mediated interaction, rhFNHN29 and rhFNHC36
inhibited the MHCC97H cell migration toward the FN
concentration gradient, as well as adhesion to the FN
substrate. Previous studies have confirmed that human
recombinant fibronectin polypeptide CH50 has the abil-
ity to interfere with the expression and activity of integ-
rin ava n db3, resulting in the inhibition of invasive
growth of tumor cells and angiogenesis [13], and a 22-
mer FN peptide, termed FNIII14, has also been shown
to inhibit b1 integrin-mediated adhesion without bind-
ing to integrins and has exhibited the potential to pre-
vent lymphoma cell metastasis [14]. It is understood
that no basement membranes exist under liver sinusoi-
dal endothelial cells, thus liver cancer cells can not have
the same adhesion to laminin or collagen as other
tumor cells, and so it follows that integrin-mediated
Figure 7 Effects of rhFNHN29 and rhFNHC36 on tyrosine phosphorylation of FAK and activation of AP-1. (A), Effect of PAO on the anti-
adhesive activity of rhFNHN29 and rhFNHC36. MHCC97H cell suspension (2 × 10
5/100 μl) with or without Mn
2+(0.1 mM), with or without PAO
(20 μM) were pretreated with FN, rhFNHN29 and rhFNHC36 (200 μg/ml), respectively, and then seeded in a 96-well plate coated with or without
FN (2.5 μg/ml). Adhesion of MHCC97H cells to the FN substrate was assayed under the indicated conditions as described in Figure 2. (B),
Immunoblotting of p125
FAK and EMSA of activated AP-1. MHCC97H cells were deprived of serum for 10 h, incubated in DMEM with or without
PAO (20 μM) for 5 min, and further cultured with Mn
2+(0.1 mM) in the presence or absence of FN, rhFNHN29 and rhFNHC36 (200 μg/ml) at 37°C
for 20 min. The cytoplasmic protein and the nuclear protein were extracted respectively. The phosphotyrosyl proteins electroblotted to the PVDF
membrane were visualized by anti-p-FAK (Tyr 397) after SDS-PAGE, and the activated AP-1 electroblotted to Nylon membrane was visualized by
specific HRP-labeled probe after 6.5% PAGE for nuclear protein (F zone indicates non-binded free probe).
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role in the formation of metastases [32-34]. This
involves several types of FN receptors, such as a4, a5,
ava n db1, b3i n t e g r i ns u b u n i t ,o fw h i c hi n t e g r i navb3
is the key element that mediates liver cancer invasion
and metastasis due to low expression in normal tissue
but high expression in HCC [34]. Therefore, interven-
tion with FN-type peptides is more suitable for liver
cancer cells that express a4, a5, av, b1o rb3 integrin.
The Integrin-FAK-AP-1 signaling pathway plays an
important role in cell adhesion, proliferation, migration,
differentiation, etc. [35]. Intracellular signaling involves
the accumulation of several proteins such as focal adhe-
sion kinase (FAK), which is mainly distributed in the
adhesion plaque (FAP) structure. After the extracellular
domain of integrin a subunit contacts the ECM, the
integrins on the membrane cluster and further activate
adhesion kinase (FAK phosphorylation) and other pro-
tein kinases [36,37]. The nuclear target proteins, includ-
ing AP-1 transcription factor, receive the activated
signal and further control gene expression. During the
adhesion and invasion process of hepatocellular carci-
noma cells, the tyrosine kinase-mediated signaling path-
ways induced by integrin receptors are of great
importance [38]. In this study, it was found that
rhFNHN29 and rhFNHC36 inhibit MHCC97H cell
adhesion and invasion by blocking the integrin-FAK-
AP-1 pathway. Expression of p-FAK was exhibited when
a tyrosine phosphatase inhibitor (PAO) was added, sug-
gesting that the interaction between rhFNHN29 or
rhFNHN36 and integrin alpha V beta 3 results in the
blockage of a series of signals into the nucleus including
the AP-1 activation signal. The promoters regulated by
AP-1 include TRE of integrins [39] and MMPs [40],
which contain AP-1 binding sites, and TPA response
elements [41]. It was also found that the inhibitory
impact of rhFNHC36 on integrin and MMP9 expression
exhibited dose-dependence, but impact of rhFNHN29
on integrin expression required a high concentration.
The rhFNHC36 polypeptide is more effective than
rhFNHN29 due to the following: 1) although both
rhFNHN29 and rhFNHC36 contain a heparin-binding
domain, rhFNHC36 contains another anti-adhesion site,
YTIYVIAL, which was found by Kato [14]. This anti-
adhesive site is buried within the type III module struc-
ture in plasma FN, however, it is exposed in rhFNHC36.
2) AP-1 transcription factors are leucine zipper proteins
that bind to a consensus DNA sequence (5′-TGAG/
CTCA-3′) as a dimeric complex. Various AP-1 dimers
bind to DNA with differing affinities. The dimers of AP-
1 bound with MMP9 promoter DNA are greater than
that of MMP2 [40,42], hence regulation of AP-1 due to
MMP9 expression is more sensitive than through
M M P 2e x p r e s s i o n .W es p e c u l a t e dt h a tt h r o u g ht h e
integrin-FAK-AP-1 pathway the effect of rhFNHC36 on
MMP9 activity by AP-1 may be greater than the effect
of rhFNHN29 in MHCC97H cells.
In this study our intervention is targeted. Different
tumor cells express different integrins and MMPs,
which are often associated with a different potential for
tumor invasion and metastasis. In previous reports,
mRNA expression levels of integrins and MMPs have
been analysed using a panel of human tumor cell lines
with different degrees of differentiation and potential for
tumor formation, tissue invasion, and metastasis [23,24].
In this study, the mRNA expression of integrins and
MMPs that was detected in different liver cancer cell
lines and MHCC97H cells was found to feature low
levels of integrin a5 mRNA expression and high levels
of integrin av, integrin b1, integrin b3, MMP1, MMP2
and MMP9 mRNA expression. This may partly contri-
bute to its invasion and metastasis, indicating that
MHCC97H cells can be used as a model for the study
of anti-invasion and anti-metastasis.
In summary, our work provides the first evidence that
rhFNHN29 and rhFNHC36 may play an important role
in safeguarding against human liver cancer through the
reduction of integrin expression level and MMP-9 activ-
ity and may shed light on a novel strategy for liver can-
cer therapy.
Conclusions
We found that both rhFNHN29 and rhFNHC36 poly-
peptides were able to inhibit the adhesion and invasion
of MHCC97H cells, and moreover abrogate the tyrosine
phosphorylation of focal adhesion kinase (p-FAK) and
activation of activator protein 1 (AP-1), which resulted
in the decrease of integrin av, b3 and b1 expression and
the reduction of MMP-9 activity. These findings suggest
that rhFNHN29 and rhFNHC36 may play an important
role in controlling human liver cancer invasion.
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